Oral Drug Archives - Page 2 of 3 - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Vepdegestrant Hits Primary Endpoint in Phase III Breast Cancer Trial

Clinical Trial News

Camizestrant Combo Therapy Supports First-Line Use in AstraZeneca’s Breast Cancer Trial

February 27, 2025

Ctexli (Chenodiol) Gains FDA Approval as First CTX Treatment

February 25, 2025

Business & Finance News

Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger

February 21, 2025

Romvimza (Vimseltinib) for TGCT: FDA Approves Oral CSF1-Targeted Drug

February 19, 2025

Clinical Trial News

Nerandomilast Achieves Positive Phase III Results in Progressive Pulmonary Fibrosis

February 12, 2025

Clinical Trial News

Cenerimod Reduces SLE Disease Activity, Paves the Way for Phase III

December 30, 2024

Clinical Trial News

Obicetrapib Lowers LDL-C as Monotherapy and with Ezetimibe in Phase III Trials

December 26, 2024

Clinical Trial News

Rilzabrutinib Sets a New Benchmark in Immune Thrombocytopenia Trials

December 10, 2024

Clinical Trial News

Obicetrapib-Ezetimibe Combo Cuts LDL-C in TANDEM Trial

November 22, 2024

Clinical Trial News

Merck’s Pimicotinib Shows Promise in Expanding TGCT Options

November 13, 2024

Business & Finance News

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

November 6, 2024

Clinical Trial News

Orismilast Closer to Phase III as a Promising Oral Treatment for Atopic Dermatitis

September 30, 2024

Aqneursa Joins the Ranks with Miplyffa, Expands Niemann-Pick Disease Type C Treatments

September 25, 2024

New Brain Tumor Drug Voranigo (Vorasidenib) Targets Grade 2 IDH-Mutant Glioma

August 21, 2024

Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata Patients

Next Page »